Data_Sheet_1_Effects of sacubitril/valsartan on life quality in chronic heart failure: A systematic review and meta-analysis of randomized controlled trials.docx

AimsSacubitril/valsartan has been demonstrated to have cardiovascular benefits in patients with chronic heart failure (CHF). We aimed to conduct a meta-analysis of its effects on life quality in patients with CHF, in comparison with the angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB).MethodsPubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov were searched from inception through March 2022 for all relevant randomized controlled trials assessing the impact of sacubitril/valsartan and ACEI/ARB on health-related quality of life (HRQoL) in patients with CHF. Two reviewers independently conducted study selection, data extraction, and assessment of bias and quality of evidence. Review Manager 5.3 software was used for meta-analysis.ResultsWe included 10 clinical studies involving 10,426 patients with heart failure with reduced ejection fraction (HFrEF) and 7,689 patients with heart failure with preserved ejection fraction (HFpEF). Meta-analysis results showed that, in terms of the primary outcome, the sacubitril/valsartan group was superior than the ACEI/ARB group in improving HRQoL of HFrEF, and the difference was statistically significant (SMD 1.26; 95% CI: 0.14, 2.37; p = 0.03), while there was no significant difference between the two groups in HFpEF (SMD 0.37; 95% CI: −0.35, 1.09; p = 0.32). The effect of sacubitril/valsartan on the secondary outcome of the minimal important improvement rate of HRQoL in HFrEF was consistent with the primary outcome, while the effect in HFpEF was not clear. The descriptive analysis of individual studies indicated no significant difference in the improvement of 6-min walk distance between the two groups.ConclusionSacubitril/valsartan is beneficial to improve HRQoL outcome in patients with HFrEF with high quality of evidence. Compared with ACEI/ARB, sacubitril/valsartan was more effective. While in patients with HFpEF, this improvement was similar between the two groups.</p

Table_1_Effects of sacubitril/valsartan on life quality in chronic heart failure: A systematic review and meta-analysis of randomized controlled trials.docx

AimsSacubitril/valsartan has been demonstrated to have cardiovascular benefits in patients with chronic heart failure (CHF). We aimed to conduct a meta-analysis of its effects on life quality in patients with CHF, in comparison with the angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB).MethodsPubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov were searched from inception through March 2022 for all relevant randomized controlled trials assessing the impact of sacubitril/valsartan and ACEI/ARB on health-related quality of life (HRQoL) in patients with CHF. Two reviewers independently conducted study selection, data extraction, and assessment of bias and quality of evidence. Review Manager 5.3 software was used for meta-analysis.ResultsWe included 10 clinical studies involving 10,426 patients with heart failure with reduced ejection fraction (HFrEF) and 7,689 patients with heart failure with preserved ejection fraction (HFpEF). Meta-analysis results showed that, in terms of the primary outcome, the sacubitril/valsartan group was superior than the ACEI/ARB group in improving HRQoL of HFrEF, and the difference was statistically significant (SMD 1.26; 95% CI: 0.14, 2.37; p = 0.03), while there was no significant difference between the two groups in HFpEF (SMD 0.37; 95% CI: −0.35, 1.09; p = 0.32). The effect of sacubitril/valsartan on the secondary outcome of the minimal important improvement rate of HRQoL in HFrEF was consistent with the primary outcome, while the effect in HFpEF was not clear. The descriptive analysis of individual studies indicated no significant difference in the improvement of 6-min walk distance between the two groups.ConclusionSacubitril/valsartan is beneficial to improve HRQoL outcome in patients with HFrEF with high quality of evidence. Compared with ACEI/ARB, sacubitril/valsartan was more effective. While in patients with HFpEF, this improvement was similar between the two groups.</p

Theoretical Analysis of Built-in Interfacial Electric Dipole Field in Dye-Sensitized Solar Cells

The built-in electric field formed between the involved species at the heterogeneous interface can affect the overall performance of dye-sensitized solar cells (DSSCs). The direct experimental observation on the built-in electric field is challenging due to the intricate heterogeneous interface itself. Herein, we propose a novel strategy for exploring the nature of the built-in electric field in the functionality of DSSCs by using externally applied electric field as perturbation to couple to the built-in electric field. As a matter of fact, the built-in electric field refers to the interfacial electric field (Fdipole) induced by the charge separation occurring at heterogeneous dye/semiconductor interface. On the basis of theoretical calculations, we found that Fdipole couples to external electric field through the electric dipole moment change (ΔμET) at dye/semiconductor heterointerface to affect the photoelectronic properties in DSSCs. In essence, the influence of gap states and conduction bands is determined by the overlap between the applied electric field and intrinsic dipole moment change of charge-separated dye/semiconductor. Furthermore, the electron-transfer rate (kET) is also intrinsically related to the coupling of Fdipole with external electric field in the form of electric dipole moment at dye/semiconductor interface. In addition, applying external electric field is demonstrated to be an approach to modulate the interfacial electric dipole moment field to achieve better performance of DSSCs. Our theoretical finding can provide insight into designed strategies for understanding the functionality of DSSCs and offer a universal route to study the heterogeneous interfaces in DSSCs experimentally and theoretically

Data_Sheet_1_SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.docx

ObjectiveTo investigate the effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with diabetes with cardiovascular disease (CVD) or at high cardiovascular risk.DesignSystematic review and meta-analysis of randomized controlled trials (RCTs).Data sourcesPubmed, Embase, the Cochrane Library, and ClinicalTrial.gov from their inception to August 28, 2021.Review methodsRandomized control trials (RCTs) assess the effects of SGLT2i in patients with diabetes with cardiovascular disease or at high cardiovascular risk. Primary outcomes included the composite outcome of cardiovascular death (CV death) and hospitalization for heart failure (HHF), HHF, and renal composite outcomes. Secondary outcomes included major adverse cardiovascular events (MACE), CV death, all-cause mortality, and change from the baseline in HbA1c. Additionally, we assessed the effects of treatment in prespecified subgroups on the combined risk of primary and secondary outcomes. These subgroups were based on history of heart failure (HF), estimated glomerular filtration rate (eGFR) levels, and history of hypertension (HTN). A meta-analysis was carried out by using fixed effect models to calculate hazard ratio (HR) or mean difference (MD) between the SGLT2i administrated groups and the control groups.ResultsFour major studies (n = 42,568) were included. Primary outcomes showed that SGLT2i was associated with significantly lower risk of CV death/HHF (HR, 0.90; 95% confidence interval, 0.84 to 0.98; P for heterogeneity = 0.01), HHF (HR, 0.84; 95% CI, 0.73 to 0.98; p = 0.02), and renal composite outcomes (HR, 0.83; 95%CI, 0.74 to 0.92; p = 0.0007) in patients with diabetes with CVD or at high CV risk. Secondary outcome showed that the use of SGLT2i was associated with significant reduction of the HbA1c level (MD, −0.30; 95% CI, −0.36 to −0.23; p ConclusionsThe SGLT2i showed benefits on CV death/HHF, HHF, renal composite outcomes, and HbA1c reduction in patients with diabetes with CVD or at high CV risk. The benefits of improving renal composite outcomes were observed only in patients with diabetes without HF history.Systematic Review RegistrationPROSPERO CRD42021227400</p

Screening and quantification of fourteen synthetic antidiabetic adulterants in herbal pharmaceuticals and health foods by HPLC and confirmation by LC-Q-TOF-MS/MS

A procedure was established and fully validated for the screening and quantification of fourteen synthetic antidiabetic adulterants in herbal pharmaceuticals and health foods, including metformin (MF), buformin (BF), phenformin (PHF), rosiglitazone (RGZ), pioglitazone (PGZ), chlorpropamide (CPM), glipizide (GPZ), tolbutamide (TBM), gliclazide (GCZ), glibenclamide (GBM), glimepiride (GMR), repaglinide (RGN), gliquidone (GQD) and nateglinide (NGN). The samples were extracted by methanol and separated by HPLC. Retention times and ultraviolet spectra were used for the preliminary screening, and the suspected adulterants were then confirmed by liquid chromatography-quadrupole-time of flight mass spectrometry (LC-Q-TOF-MS/MS) and quantified by HPLC. The developed procedure was successfully applied to assess twenty-four herbal samples, and PHF, GCZ, GBM, MF, GPZ and BF were found in many. To the best of our knowledge, this is the first report of simultaneous screening and quantification of these fourteen synthetic antidiabetic adulterants from any matrix.</p

Intersubunit Electron Transfer (IET) in Quantum Dots/Graphene Complex: What Features Does IET Endow the Complex with?

First principles calculations of quantum dots (QDs)/graphene (QDs/GR) hybrid nanomaterials were performed to investigate the interfacial electron–hole separation process at the atomistic level for verifying the tentative mechanism and unveiling the functionalities endowed by the intersubunit electron transfer. Our calculated results unveil the intersubunit electron transfer mechanism of QDs/GR nanomaterials: upon visible light adsorption, the ground electron of CdS QD in nanomaterials is first promoted to the excitated state, which then injects into the conduction band of graphene and transports along graphene layer through π* orbitals to achieve interfacial electron–hole separation. Adiabatic and nonadiabatic methods are used to estimate the electron transfer time at the heterogeneous interface from CdS QD to graphene. Our findings suggest a new route to facilitate the design of QDs@GR based nanodevices

Data_Sheet_2_SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.docx

ObjectiveTo investigate the effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with diabetes with cardiovascular disease (CVD) or at high cardiovascular risk.DesignSystematic review and meta-analysis of randomized controlled trials (RCTs).Data sourcesPubmed, Embase, the Cochrane Library, and ClinicalTrial.gov from their inception to August 28, 2021.Review methodsRandomized control trials (RCTs) assess the effects of SGLT2i in patients with diabetes with cardiovascular disease or at high cardiovascular risk. Primary outcomes included the composite outcome of cardiovascular death (CV death) and hospitalization for heart failure (HHF), HHF, and renal composite outcomes. Secondary outcomes included major adverse cardiovascular events (MACE), CV death, all-cause mortality, and change from the baseline in HbA1c. Additionally, we assessed the effects of treatment in prespecified subgroups on the combined risk of primary and secondary outcomes. These subgroups were based on history of heart failure (HF), estimated glomerular filtration rate (eGFR) levels, and history of hypertension (HTN). A meta-analysis was carried out by using fixed effect models to calculate hazard ratio (HR) or mean difference (MD) between the SGLT2i administrated groups and the control groups.ResultsFour major studies (n = 42,568) were included. Primary outcomes showed that SGLT2i was associated with significantly lower risk of CV death/HHF (HR, 0.90; 95% confidence interval, 0.84 to 0.98; P for heterogeneity = 0.01), HHF (HR, 0.84; 95% CI, 0.73 to 0.98; p = 0.02), and renal composite outcomes (HR, 0.83; 95%CI, 0.74 to 0.92; p = 0.0007) in patients with diabetes with CVD or at high CV risk. Secondary outcome showed that the use of SGLT2i was associated with significant reduction of the HbA1c level (MD, −0.30; 95% CI, −0.36 to −0.23; p ConclusionsThe SGLT2i showed benefits on CV death/HHF, HHF, renal composite outcomes, and HbA1c reduction in patients with diabetes with CVD or at high CV risk. The benefits of improving renal composite outcomes were observed only in patients with diabetes without HF history.Systematic Review RegistrationPROSPERO CRD42021227400</p

Spin-Enhanced Reverse Intersystem Crossing and Electroluminescence in Copper Acetate-Doped Thermally Activated Delayed Fluorescence Material

Thermally activated delayed fluorescence (TADF) materials are attractive for next-generation organic light-emitting diodes (OLEDs) because of their utilization of nonradiative triplets via reverse intersystem crossing (RISC), which requires not only a small singlet–triplet energy splitting but also the conservation of spin angular momentum. Here we use copper acetate as a spin sensitizer to facilitate RISC and thus enhance electroluminescence in TADF-exciplex OLEDs. Copper acetate is involved in the radiative decay process due to its coordination interaction with exciplex molecules having intermolecular charge-transfer characteristics, which causes significant changes in the photoluminescence intensity and lifetime. Meanwhile, magneto-photoluminescence reveals that the addition of copper acetate promotes spin conversion in the RISC process. It allows the enhancement of the electroluminescence (∼80%) from spin-sensitized OLEDs, accompanied by the suppression of magneto-electroluminescence upon the doping of copper acetate. These results illustrate that using a spin sensitizer may overcome the limitation of harvesting nonradiative triplets in organic luminescent materials and devices

Additional file 1 of Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes

Additional file 1: Figure S1. Quality control in the proteomics analysis. Figure S2. Venn analysis of differential proteins and lipids. Figure S3. PCA score plots of lipidomic analysis in plasma from human. Figure S4. Validation plots of the OPLS-DA models obtained using 200 permutation tests in plasma. Figure S5. Box plots for validation of ALDOC analyzed by ELISA. Table S1. Characteristics of the subjects. Table S2. List of TOF/MS parameters, Ionspray voltage floating (ISVF), The turbo spray temperature (TEM), Nebulizer gas (Gas 1), Heater gas (Gas 2), Curtain gas Declustering potential (DP), Collision energy in MS (CE in MS) and Collision energy in MS/MS (CE in MS/MS), Nebulizer and auxiliary gas, and scan range for positive and negative ionization mode. Table S5. Precision, repeatability and stability in the method validation of the plasma samples in positive mode. Table S6. Precision, repeatability and stability in the method validation of the plasma samples in negative mode. Table S7. The absolute values of correlation coefficients (|r|) between the proteomics results and the lipidomics results in NSCLC patients

Data_Sheet_1_Functional Verification of Two Genes Related to Stripe Rust Resistance in the Wheat-Leymus mollis Introgression Line M8664-3.pdf

Stripe rust, caused by Puccinia striiformis f. sp. tritici (Pst), is one of the most widespread and destructive fungal diseases of wheat worldwide. The cultivation and growth of resistant wheat varieties are the most economical, effective, and environmental friendly methods to control stripe rust. Therefore, it is necessary to use new resistance genes to breed resistant wheat varieties. A single dominant gene temporarily designated as YrM8664-3, from a wheat-Leymus mollis introgression line M8664-3 highly resistant to Chinese predominant Pst races, is a potentially valuable source of stripe rust resistance for breeding. Herein, based on previous YrM8664-3 chromosome location results (bin 4AL13-0.59-0.66 close to 4AL12-0.43-0.59) and expression change information of candidate genes and bioinformatics analysis, several candidate genes with significantly different expression changes were then selected and verified by virus-induced gene silencing (VIGS). Two of the candidate genes temporarily designated as TaFBN [containing plastid lipid-associated proteins (PAP)_fibrillin domain in its protein] and Ta_Pes_BRCT [containing Pescadillo and breast cancer tumour suppressor protein C-terminus (BRCT) domain in its protein], produced the most significant resistance changes in the wheat-Pst interaction system after silencing. These two genes were further verified by Agrobacterium-mediated wheat genetic transformation technology. According to the identification of disease resistance, the resistance function of the candidate gene TaFBN was further verified. Then, the expression of TaFBN under hormone treatment indicated that TaFBN may be related to the salicylic acid (SA) and abscisic acid (ABA) signaling pathways. Combined with the expression of TaFBN in response to environmental stress stimulation, it can be reasonably speculated that TaFBN plays an important role in the resistance of wheat to Pst and is involved in abiotic stress pathways.</p